^
Association details:
| Biomarker: | MYB-TYK2 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Zolinza (vorinostat) (HDAC inhibitor) + cerdulatinib (ALXN2075) (SYK inhibitor, JAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia
Published date:
01/12/2022
Excerpt:
...in vivo models of B-cell ALL from a patient harboring the MYB-TYK2 fusion gene...vorinostat and cerdulatinib in pre-clinical models of MYB-TYK2-rearranged ALL demonstrated that both drugs exhibited anti-leukemic effects and reduced the disease burden in treated mice.
DOI:
https://doi.org/10.1038/s41417-021-00421-6
